Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin in Advanced NSCLC Patients With Anorexia-Cachexia
NCT03637816Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anamorelin in anorexia nervosa (AN), cachexia, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2018; status: active, not recruiting.
02
Drugs
anamorelin
03
Conditions
anorexia nervosa (AN)cachexia
Beyond the preview
Go deeper on NCT03637816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637816.